MD Anderson Cancer Center and Biocept, Inc. Study Reveals HER2+ CTCs and DTCs in Patients With HER2- Tumors by Tissue Analysis
6/4/2013 11:17:26 AM
More...
|
Biocept, Inc. to Present at the American Association for Cancer Research Annual Meeting on Ability of its CEE-SelectorTM Technology to Enhance the Sensitivity of Sequencing for Rare Mutation Detection
4/5/2013 6:30:37 AM
More...
|
Biocept, Inc. to Present at the 103rd American Association for Cancer Research Annual Meeting on New Analytic Methods for Circulating Tumor Cell Analysis, Including SelectorTM, Ultra-Sensitive Mutation Detection Technology
4/2/2012 10:35:47 AM
More...
|
Biocept, Inc. to Present at the Molecular Medicine Tri-Conference on Circulating Tumor Cell (CTC) Technologies
2/22/2012 6:46:49 AM
More...
|
Biocept, Inc. to Present at the Molecular Medicine Tri-Conference on Circulating Tumor Cell (CTC) Technologies
2/21/2012 11:39:05 AM
More...
|
Biocept, Inc. Announces New Methods for Isolating Previously Unrecognized Circulating Tumor Cells (CTCs)
12/15/2011 10:40:52 AM
More...
|
Biocept, Inc. Announces Allowance of Key Patent for its Circulating Tumor Cell Platform
11/10/2011 5:52:13 AM
More...
|
Biocept, Inc. Publishes on Mechanics and Performance of Its OncoCEE(TM) Platform for Circulating Tumor Cells (CTCs) in Cancer Patients
9/29/2011 5:58:56 AM
More...
|
Biocept, Inc. and Clarient, Inc. Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients
8/25/2011 11:07:39 AM
More...
|
Biocept, Inc. Announces Availability of Its New Breast Cancer Test, OncoCEE-BR™ Utilizing Circulating Tumor Cells (CTCs)
7/29/2011 10:06:38 AM
More...
|
|